These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 3523546)

  • 21. [Long-term D-penicillamine therapy of Wilson's disease in childhood. Changes in blood coagulation and effects on the haematopoetic system].
    Hayek HW; Schnack H; Widhalm S
    Wien Klin Wochenschr; 1973 Feb; 85(8):122-5. PubMed ID: 4632215
    [No Abstract]   [Full Text] [Related]  

  • 22. Discontinuation of penicillamine in the absence of alternative orphan drugs (trientine-zinc): a case of decompensated liver cirrhosis in Wilson's disease.
    Ping CC; Hassan Y; Aziz NA; Ghazali R; Awaisu A
    J Clin Pharm Ther; 2007 Feb; 32(1):101-7. PubMed ID: 17286794
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Membranoproliferative glomerulonephritis in a patient with Wilson's disease.
    Ozçakar ZB; Ekim M; Ensari A; Kuloglu Z; Yüksel S; Acar B; Kirsaçlioglu C; Kansu A; Yalçinkaya F; Girgin N
    J Nephrol; 2006; 19(6):831-3. PubMed ID: 17173260
    [TBL] [Abstract][Full Text] [Related]  

  • 24. D-penicillamine-induced IgA deficiency in Wilson's disease.
    Proesmans W; Jaeken J; Eeckels R
    Lancet; 1976 Oct; 2(7989):804-5. PubMed ID: 61477
    [No Abstract]   [Full Text] [Related]  

  • 25. Results of treatment of Wilson's disease--own observations.
    Jabłońska-Kaszewska I; Drobińska-Jurowiecka A; Dabrowska E; Trocha H
    Med Sci Monit; 2003 Aug; 9 Suppl 3():9-14. PubMed ID: 15156603
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Systemic lupus erythematosus induced by d-penicillamine in Wilson's disease: apropos of a case].
    López-Guerra N; Alvarez Lario B; García-Moncó C; Peña Sagredo JL
    Med Clin (Barc); 1987 Apr; 88(13):552-4. PubMed ID: 3586738
    [No Abstract]   [Full Text] [Related]  

  • 27. Zinc therapy increases duodenal concentrations of metallothionein and iron in Wilson's disease patients.
    Sturniolo GC; Mestriner C; Irato P; Albergoni V; Longo G; D'Incà R
    Am J Gastroenterol; 1999 Feb; 94(2):334-8. PubMed ID: 10022625
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Elastosis perforans serpiginosa secondary to D-penicillamine treatment in a Wilson's disease patient.
    Deguti MM; Mucenic M; Cancado EL; Tietge UJ
    Am J Gastroenterol; 2002 Aug; 97(8):2153-4. PubMed ID: 12190204
    [No Abstract]   [Full Text] [Related]  

  • 29. Neuromuscular transmission and acetylcholine receptor antibodies in penicillamine-treated Wilson's disease patients.
    Anlar B; Kuruoğlu R; Varli K; Topçu M
    Muscle Nerve; 1996 May; 19(5):676-7. PubMed ID: 8618573
    [No Abstract]   [Full Text] [Related]  

  • 30. [Antibodies to D-penicillamine in patients with chronic polyarthritis--diagnostic aid in undesired and insufficient drug effects?].
    Storch W; Keitel W
    Z Rheumatol; 1988; 47 Suppl 1():44-7. PubMed ID: 3213272
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Pemphigus in a patient treated with penicillamine for Wilson's disease].
    Degos R; Touraine R; Belaïch S; Revuz J
    Bull Soc Fr Dermatol Syphiligr; 1969; 76(6):751-3. PubMed ID: 5384189
    [No Abstract]   [Full Text] [Related]  

  • 32. [Pathogenesis and treatment of Wilson's disease].
    Nagy J; Vincze Z; Folhoffer A; Horváth A; Csák T; Zelkó R
    Acta Pharm Hung; 2003; 73(4):237-41. PubMed ID: 15279036
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transient fetal myelosuppressive effect of D-penicillamine when used in pregnancy.
    Yalaz M; Aydogdu S; Ozgenc F; Akisu M; Kultursay N; Yagci RV
    Minerva Pediatr; 2003 Dec; 55(6):625-8. PubMed ID: 14676735
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Penicillamine-induced arthropathy in Wilson's disease.
    Walshe JM; Golding DN
    Proc R Soc Med; 1977; 70 Suppl 3(Suppl 3):4-6. PubMed ID: 122670
    [No Abstract]   [Full Text] [Related]  

  • 35. Penicillamine hypersensitivity: successful desensitization of a patient with severe hepatic Wilson's disease.
    Chan CY; Baker AL
    Am J Gastroenterol; 1994 Mar; 89(3):442-3. PubMed ID: 8122662
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Laboratory changes and complications during long-term therapy of Wilson's disease using D-penicillamine].
    Hauftová D; Slavícek J; Hartl J; Seidlová V; Komenda S
    Vnitr Lek; 1970 Apr; 16(4):344-53. PubMed ID: 5443326
    [No Abstract]   [Full Text] [Related]  

  • 37. The metabolism and pharmacology of D-penicillamine in man.
    Perrett D
    J Rheumatol Suppl; 1981; 7():41-50. PubMed ID: 7014876
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Treatment of Wilson's disease with zinc. 5 cases].
    Bona I; Broussolle E; Neuschwander P; Confavreux C; Fontanges T; Accominotti M; Chazot G
    Rev Neurol (Paris); 1993; 149(6-7):393-7. PubMed ID: 8303158
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The influence of prolonged treatment with D-penicillamine on the immune response in Wilson's disease.
    Czlonkowska A
    Eur J Clin Pharmacol; 1977 Dec; 12(4):265-71. PubMed ID: 590312
    [TBL] [Abstract][Full Text] [Related]  

  • 40. D-penicillamine induced Goodpasture's syndrome in Wilson's disease.
    Sternlieb I; Bennett B; Scheinberg IH
    Ann Intern Med; 1975 May; 82(5):673-6. PubMed ID: 1094875
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.